Further strengthening the link between cardiometabolic variables and inflammation, in a previous analysis on the present population, we have found that obesity (defined as a Body Mass Index > 30) is associated with a statistically significant increase in the risk of a poor treatment response in PsA subjects receiving TNF-α blockers [28]. The gene discussed is TNF; the disease is obesity disorder.